Scientia Advisors in the News

---

Publications

---

Press Releases

---

Events

---

Luminary Insights

---

Media Contact

---

Scientia Advisors in the News

European Biotechnology News Quotes Harry Glorikian in "Personalised Medicine: A new force for new biopharma deals"

Constantine Theodoropulos
European Biotechnology News - Issue 01-02/2011

In this article entitled "Personalised Medicine: A new force for new biopharma deals", Constantine Theodoropulos quotes Harry Glorikian, Managing Partner at Scientia Advisors, on the emerging players involved the healthcare ecosystem due to the shift to personalized medicine. According to Glorikian, "Where the stakeholders used to be only pharmaceutical companies, now regulators are getting involved and changing the rules. Furthermore, payers are getting involved and are ready to pay a premium for effective diagnostic tests that validate a therapeutic course of treatment, or not. This also has the consent of patients and physicians who are passionate about the promise of personalized medicine."

The article also discusses how European regulators and payers adapt to the changing rules of personalized medicine and the issues for successful diagnostics deal making.

The article is available to subscribers at European Biotechnology News.